Difference between revisions of "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial"
Jump to navigation
Jump to search
(Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://www.medrxiv.org/content/10.1101/2020....") |
|||
| Line 23: | Line 23: | ||
== Major Issues == | == Major Issues == | ||
| − | No major issues identified. | + | No major issues identified at this time. |
== Minor Issues == | == Minor Issues == | ||
| − | No minor issues identified. | + | No minor issues identified at this time. |
== Impact == | == Impact == | ||
Latest revision as of 17:09, 22 July 2020
| Publication | |
| Title | |
| Authors |
|
| Journal | medRxiv preprint |
| Date | April 10, 2020 |
A randomized clinical trial of 62 patients who received hydroxychloroquine or standard therapy showed patients who received hydroxychloroquine had a significantly shorter time to body temperature recovery and cough remission. Notably, 4 patients (13%) in the control group progressed to severe illness whereas no patients treated with hydroxychloroquine progressed.
Major Issues
No major issues identified at this time.
Minor Issues
No minor issues identified at this time.
Impact
This study demonstrated some clinical benefit for hydroxychloroquine in treatment of early stage COVID-19 disease where patients received treatment on average 2.2 days after fever onset and 2 days after cough onset.
Article Revisions
None at this time.